Moody’s assigns ‘Baa3’ rating to OU Medicine’s bonds

Moody’s Investors Service assigned its “Baa3” rating to Oklahoma City-based OU Medicine’s proposed $1 billion series 2018B and $251 million series 2018C revenue bonds.

Advertisement

The assignment is a result of several factors, including OU Medicine’s favorable market position, close ties with the University of Oklahoma, healthy cashflow margins and a strong management team that Moody’s expects will effectively lead the system through the transition to a nonprofit healthcare system.  Moody’s also acknowledged the health system’s increasingly competitive market, high leverage metrics, modest liquidity and high reliance on Medicaid and self-pay payers.

The outlook is stable, reflecting Moody’s expectation that OU Medicine will maintain strong margins during the transition period because of the tenured management team and well-planned transition strategy.

More articles on healthcare finance:
Donations to USC medical school fall 55% after dean, faculty scandals
U of Texas Health renames cancer center after donors of $25M gift
10 recent hospital, health system outlook and credit rating actions

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.